Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Acquired demyelinating neuropathies].

A F Hahn1

  • 1Department of Clinical Neurosciences, London Health Sciences Center, Ontario, Canada.

La Revue Du Praticien
|June 15, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cold-induced sweating syndrome: CISS1 and CISS2: manifestations from infancy to adulthood. Four new cases.

Journal of the neurological sciences·2010
Same author

Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy.

Journal of the neurological sciences·2008
Same author

CMT1X phenotypes represent loss of GJB1 gene function.

Neurology·2007
Same author

Cold-induced sweating syndrome: a report of two cases and demonstration of genetic heterogeneity.

Journal of the neurological sciences·2006
Same author

Reliability and validity of the CMT neuropathy score as a measure of disability.

Neurology·2005
Same author

Rigid spine muscular dystrophy due to SEPN1 mutation presenting as cor pulmonale.

Neurology·2005
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Acquired demyelinating polyneuropathies are autoimmune disorders. Guillain-Barré syndrome, often triggered by infections like Campylobacter jejuni, involves immune cross-reactions with nerve tissues, treatable with immunomodulation.

Area of Science:

  • Neuroimmunology
  • Autoimmune diseases
  • Peripheral neuropathies

Context:

  • Acquired demyelinating polyneuropathies (ADPs) encompass acute and chronic presentations, recognized as autoimmune disorders.
  • Guillain-Barré syndrome (GBS) is an acute, self-limited autoimmune disease often precipitated by infections, notably Campylobacter jejuni, Cytomegalovirus, and Epstein-Barr virus.
  • The immunopathogenesis of chronic forms like chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN) is less understood.

Purpose:

  • To elucidate the autoimmune mechanisms underlying acquired demyelinating polyneuropathies, including Guillain-Barré syndrome.
  • To explore the role of molecular mimicry in GBS pathogenesis, where immune responses to infections cross-react with neural tissues.
  • To review current immunomodulatory treatment strategies for both acute and chronic forms of these neuropathies.

Related Experiment Videos

Summary:

  • GBS pathogenesis involves immune responses to infections triggering cross-reactivity with peripheral nerve gangliosides via molecular mimicry.
  • Immune reactions targeting Schwann cell/myelin epitopes cause acute inflammatory demyelinating neuropathy (90% of GBS cases); axonal forms result from reactions targeting axonal membrane epitopes.
  • Immunomodulation, including IVIg and plasma exchange, effectively shortens GBS duration, while treatments for CIDP and MMN show variable efficacy.

Impact:

  • Understanding the autoimmune basis of ADPs facilitates targeted therapeutic interventions.
  • Identifying infectious triggers and molecular mimicry mechanisms aids in predicting and potentially preventing GBS.
  • An individualized therapeutic approach optimizes outcomes for patients with these debilitating neuropathies.